IMPORTANT - EIN Presswire is proud to announce the launch of its AI-powered press release generator. Try it now!

IMPORTANT - EIN Presswire is proud to announce the launch of its AI-powered press release generator. Try it now!

World Media Directory · RSS · Email Newsletters

There were 1,197 press releases posted in the last 24 hours and 399,806 in the last 365 days.

Press Releases on September 17, 2018

1,839 Press Releases

Published on September 17, 2018 - 12:32 GMT

Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, ...

The most common side effects with Spectrila (which may affect more than 1 in 10 people) are allergic reactions (including flushing, rash, low blood pressure, hives and difficulty breathing), diarrhoea, nausea, vomiting, abdominal pain, tiredness, swelling …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:32 GMT

Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, ...

The most common side effects with Spectrila (which may affect more than 1 in 10 people) are allergic reactions (including flushing, rash, low blood pressure, hives and difficulty breathing), diarrhoea, nausea, vomiting, abdominal pain, tiredness, swelling …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Anagrelide Mylan, anagrelide, Thrombocythemia, Essential, Date of ...

Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Multiple Sclerosis, Date of authorisation: 17/03/...

Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Libtayo,Cemiplimab, decision type: , therapeutic area: , PIP number: P/...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Anagrelide Mylan, anagrelide, Thrombocythemia, Essential, Date of ...

Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Multiple Sclerosis, Date of authorisation: 17/03/...

Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Diabetes Mellitus, Type 2;Heart Failure, ...

Type 2 diabetes Forxiga was found effective in several studies in patients with type 2 diabetes. The main measure of effectiveness was the level of glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled. In two …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Diabetes Mellitus, Type 2;Heart Failure, ...

Type 2 diabetes Forxiga was found effective in several studies in patients with type 2 diabetes. The main measure of effectiveness was the level of glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled. In two …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, ...

On 21 June 2011, orphan designation (EU/3/11/872) was granted by the European Commission to S-cubed Limited, United Kingdom, for sulfonated monophosphorylated mannose oligosaccharide for the treatment of hepatocellular carcinoma. The sponsorship was …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Prevymis, letermovir, Cytomegalovirus Infections, Date of authorisation: ...

Prevymis is an antiviral medicine used to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant. Allogeneic haematopoietic stem cell transplantation involves using stem cells from a donor to …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Prevymis, letermovir, Cytomegalovirus Infections, Date of authorisation: ...

Prevymis is an antiviral medicine used to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant. Allogeneic haematopoietic stem cell transplantation involves using stem cells from a donor to …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, ...

The most common side effects with adalimumab (seen in more than 1 patient in 10) are infections (including in the nose, throat and sinuses), injection site reactions (redness, itching, bleeding, pain or swelling), headache and muscle and bone pain. Like …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, ...

The most common side effects with adalimumab (seen in more than 1 patient in 10) are infections (including in the nose, throat and sinuses), injection site reactions (redness, itching, bleeding, pain or swelling), headache and muscle and bone pain. Like …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Epoetin Alfa Hexal, epoetin alfa, Anemia;Kidney Failure, Chronic;Cancer, ...

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Epoetin Alfa Hexal, epoetin alfa, Anemia;Kidney Failure, Chronic;Cancer, ...

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Constella,linaclotide, decision type: , therapeutic area: , PIP number: ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging;Alzheimer Disease, ...

This medicinal product is for diagnostic use only. Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging;Alzheimer Disease, ...

This medicinal product is for diagnostic use only. Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on September 17, 2018 - 12:31 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq,Upadacitinib (ABT-494), decision type: , therapeutic area: , PIP ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Previous 11 12 13 14 15 16 17 18 19 20 21 Next

Previous Day 2018 Calendar Next Day